Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist

European Journal of Pharmacology

Volumn 446, Issue 1-3, 2002, Pages 129-138

  Tsukada, Junko ^a   Tahara, Atsuo ^a   Tomura, Yuichi ^a   Wada, Koh Ichi ^a   Kusayama, Toshiyuki ^a   Ishii, Noe ^a   Aoki, Motonori ^a   Yatsu, Takeyuki ^a   Uchida, Wataru ^a   Taniguchi, Nobuaki ^a   Tanaka, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Nonpeptide antagonist; Vasopressin V1A receptor; Vasopressin V2 receptor; YM471

Indexed keywords

4' [4,4 DIFLUORO 5 [2 (4 DIMETHYLAMINOPIPERIDINO) 2 OXOETHYLIDENE] 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPINE 1 CARBONYL] 2 PHENYLBENZANILIDE; OXYTOCIN RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; YM 471; 4' (4,4 DIFLUORO 5 (2 (4 DIMETHYLAMINOPIPERIDINO) 2 OXOETHYLIDENE) 2,3,4,5 TETRAHYDRO 1H 1 BENZOAZEPINE 1 CARBONYL) 2 PHENYLBENZANILIDE; 4'-(4,4-DIFLUORO-5-(2-(4-DIMETHYLAMINOPIPERIDINO)-2-OXOETHYLIDENE)-2,3,4,5-TETRAHYDRO-1H-1-BENZOAZEPINE-1-CARBONYL)-2-PHENYLBENZANILIDE; AZEPINE DERIVATIVE; DIURETIC AGENT; FUROSEMIDE; PIPERIDINE DERIVATIVE; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOASSAY; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; URINARY EXCRETION; URINE OSMOLALITY; ANIMAL; COMPARATIVE STUDY; DECEREBRATION; DEHYDRATION; DIURESIS; DRUG ANTAGONISM; DRUG EFFECT; OSMOLARITY; PATHOPHYSIOLOGY; RADIOASSAY; URINE; WISTAR RAT;

ANIMAL; AZEPINES; COMPARATIVE STUDY; DECEREBRATE STATE; DEHYDRATION; DIURESIS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUROSEMIDE; MALE; OSMOLAR CONCENTRATION; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; VASOPRESSINS; ANIMALS;

EID: 0037141763     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01813-7     Document Type: Article

References (67)

1. Role of vasopressin in abnormal water excretion in cirrhotic patients
2. Molecular cloning of the receptor for human antidiuretic hormone
3. Renin, aldosterone and arginine vasopressin in patients with liver cirrhosis: The influence of ascites retransfusion
4. 2 vasopressin receptor antagonist in normal subjects
5. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat
6. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism
7. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: Effects of highly potent analogues and competitive inhibitors
8. Calcium-mediated interactions between the antidiuretic hormone and renal plasma membranes
9. Different hormonal target sites along the mouse and rabbit nephrons
10. 50) of an enzymatic reaction
11. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake
12. Cloning and characterization of the human V3 pituitary vasopressin receptor
13. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats
14. Improvement by a non-peptide vasopressin antagonist OPC-31260 of water retention in experimental rats with myocardial infarction
15. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats
16. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats
17. Aquaretic agents: A new potential treatment of dilutional hyponatremia in cirrhosis
18. Hemodynamic effects of infused arginine vasopressin in congestive heart failure
19. 1b vasopressin receptor in rat adrenal medulla
20. Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: Relation to adenylate cyclase activation
21. Characterization of the human liver vasopressin receptor
22. 1 renal epithelial cells at physiological temperature
23. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis
24. Pharmacology and clinical perspectives of vasopressin antagonists
25. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure
26. 1b receptors
27. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus
28. Characterization of specific receptors for vasopressin in the pituitary gland
29. Antagonists of arginine-vasopressin: Experimental and clinical applications
30. Plasma atrial natriuretic hormone levels in patients with the syndrome of inappropriate antidiuretic hormone secretion
31. Pathogenesis of water and sodium retention in cirrhosis
32. 2 receptors: Synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4′,5-d][1]benzoazepine-6-carbonyl) benzanilide derivatives and 4′-(5,6-dihydro-4H-thiazolo[5,4-d] [1]benzoazepine-6-carbonyl)benzanilide derivatives
33. Sites of hormone action in the mammalian nephron
34. 1a arginine vasopressin receptor
35. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
36. Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR
37. Acquisition of a beta-adrenergic response by adult rat hepatocytes during primary culture
38. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure
39. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats
40. Identification of functional oxytocin receptors in lactating rat mammary gland in vitro
41. 2 selective ligands
42. Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome
43. Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation
44. The vasopressin-sensitive adenylate cyclase in collecting tubules and in thick ascending limb of Henle's loop of human and canine kidney
45. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy
46. 1a receptors
47. 1a antagonist, on human vascular smooth muscle cells
48. 2 receptor antagonist
49. 2 antagonist OPC-31260 in hydropenic humans
50. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease
51. 1b vasopressin receptor
52. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure
53. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells
54. 2 receptor antagonist, in vitro and in vivo
55. Characterization of human platelet vasopressin receptors
56. 1a vasopressin receptor
57. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats
58. 2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells
59. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction
60. Effects of vasopressin on human memory functions
61. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat
62. OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats
63. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist
64. 2 receptor antagonist
65. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
66. 2 antagonist, on renal function in anesthetized dogs
67. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure